An updated position statement on the management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer provides the latest evidence-based guidance, with an ...
Prescription claims data were searched to identify the first claim for raloxifene or a bisphosphonate between January 2003 and December 2004 for patients. In the commercial/Medicare data 102,750 ...
Bisphosphonates have long been established as critical agents in the treatment of bone disorders, yet recent innovations in their green synthesis are paving the way for more sustainable, efficient, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results